Literature DB >> 33738504

Early Switch From Vancomycin to Daptomycin in Methicillin-Resistant Staphylococcus aureus Bacteremia: Still More Questions Than Answers.

Sean N Avedissian1,2, Marc H Scheetz3,4, Nicolás Cortés-Penfield5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33738504      PMCID： PMC8571562          DOI： 10.1093/cid/ciab248

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

1.  Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Kimberly C Claeys; Evan J Zasowski; Anthony M Casapao; Abdalhamid M Lagnf; Jerod L Nagel; Cynthia T Nguyen; Jessica A Hallesy; Mathew T Compton; Keith S Kaye; Donald P Levine; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  Immortal Time Bias in Observational Studies.

Authors:  Kabir Yadav; Roger J Lewis
Journal:  JAMA       Date:  2021-02-16       Impact factor: 56.272

4.  Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.

Authors:  Kyle P Murray; Jing J Zhao; Susan L Davis; Ravina Kullar; Keith S Kaye; Paul Lephart; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2013-02-28       Impact factor: 9.079

5.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

6.  Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections.

Authors:  Marin L Schweizer; Kelly Richardson; Mary S Vaughan Sarrazin; Michihiko Goto; Daniel J Livorsi; Rajeshwari Nair; Bruce Alexander; Brice F Beck; Michael P Jones; Mireia Puig-Asensio; Daniel Suh; Madeline Ohl; Eli N Perencevich
Journal:  Clin Infect Dis       Date:  2021-01-29       Impact factor: 9.079

7.  Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections.

Authors:  Nobuaki Shime; Nobuyuki Saito; Miya Bokui; Naoki Sakane; Mitsuhiro Kamimura; Tsutomu Shinohara; Tadashi Kosaka; Hisashi Ishikura; Atsuko Kobayashi
Journal:  Infect Drug Resist       Date:  2018-08-06       Impact factor: 4.003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.